Akash Tewari
Stock Analyst at Jefferies
(2.58)
# 2,105
Out of 5,163 analysts
65
Total ratings
40.82%
Success rate
5.43%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $151 → $138 | $91.19 | +51.33% | 4 | Mar 10, 2026 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $580 | $469.34 | +23.58% | 1 | Mar 10, 2026 | |
| AMGN Amgen | Initiates: Hold | $350 | $366.21 | -4.43% | 1 | Mar 10, 2026 | |
| GILD Gilead Sciences | Initiates: Buy | $180 | $144.99 | +24.15% | 1 | Mar 10, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $46.52 | -24.76% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $71.19 | +34.85% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $745.77 | +11.43% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $11.29 | +130.29% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $12.18 | -17.90% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $59.08 | +15.10% | 4 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $58.51 | +62.37% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 → $16 | $10.36 | +54.44% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $177 → $189 | $129.78 | +45.63% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $18.94 | +322.39% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $985.08 | +3.04% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $27.76 | +80.12% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $71.90 | +4.31% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $39.89 | -22.29% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.58 | +46.73% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $12.70 | +41.73% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $700.45 | -26.76% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $115.61 | +8.12% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $22.88 | -51.92% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.62 | +949.38% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $60.06 | +24.89% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $444.83 | -66.05% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $41.24 | -32.10% | 3 | Oct 7, 2021 |
BioNTech SE
Mar 10, 2026
Maintains: Buy
Price Target: $151 → $138
Current: $91.19
Upside: +51.33%
Vertex Pharmaceuticals
Mar 10, 2026
Initiates: Buy
Price Target: $580
Current: $469.34
Upside: +23.58%
Amgen
Mar 10, 2026
Initiates: Hold
Price Target: $350
Current: $366.21
Upside: -4.43%
Gilead Sciences
Mar 10, 2026
Initiates: Buy
Price Target: $180
Current: $144.99
Upside: +24.15%
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $46.52
Upside: -24.76%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $71.19
Upside: +34.85%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $745.77
Upside: +11.43%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $11.29
Upside: +130.29%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $12.18
Upside: -17.90%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $59.08
Upside: +15.10%
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $58.51
Upside: +62.37%
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $10.36
Upside: +54.44%
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $129.78
Upside: +45.63%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $18.94
Upside: +322.39%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $985.08
Upside: +3.04%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $27.76
Upside: +80.12%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $71.90
Upside: +4.31%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $39.89
Upside: -22.29%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.58
Upside: +46.73%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $12.70
Upside: +41.73%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $700.45
Upside: -26.76%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $115.61
Upside: +8.12%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $22.88
Upside: -51.92%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.62
Upside: +949.38%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $60.06
Upside: +24.89%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $444.83
Upside: -66.05%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $41.24
Upside: -32.10%